Immorna
Immorna reports clinical investigation of JCXH-213, an RNA-based in vivo CAR-T candidate, in autoimmune diseases including ITP and systemic sclerosis. These are company-reported early findings, not proof of comparative efficacy; separate vaccine stages do not establish this program’s stage.
Corporate information
- Company entity
- Immorna
- Headquarters / principal office
- Research Triangle Park, North Carolina, USA; Hangzhou / Shanghai, ChinaOffice location disclosed on the corporate website; a sole legal or global headquarters is not inferred. ↗
- Founded
- 2019 ↗
- Ownership / capital status
- Not verifiedNot verified
- Official corporate reference
- https://www.immorna.com/ ↗
- LinkedIn company page
- Independent company page not verified
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
Immorna reports clinical investigation of JCXH-213, an RNA-based in vivo CAR-T candidate, in autoimmune diseases including ITP and systemic sclerosis. These are company-reported early findings, not proof of comparative efficacy; separate vaccine stages do not establish this program’s stage.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Official company contact / corporate location disclosure
- Founding / incorporation disclosure — scope stated in field